Afyx Therapeutics A/S: Financial statements 2024
CVR: 38793594
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Afyx Therapeutics A/S (CVR 38793594) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK 23,467,830 and a net result of DKK -3,810,585 compared with DKK -2,253,249 the year before. That is an increase of 266.4% compared with the year before. Equity in the 2024 report amounted to DKK 9,660,111. The solvency ratio was 62.5%. The company had 11 employees in the financial year.
- Gross Profit
- DKK 23,467,830
- Profit/Loss
- DKK -3,810,585
- Equity
- DKK 9,660,111
- Total Assets
- DKK 15,462,845
- Employees
- 11
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | 23.5M | -3.8M | 9.7M | 11 |
| 2023 | - | 6.4M | -2.3M | 4.7M | 5 |
| 2022 | - | -3.2M | -7.3M | -1M | 3 |
| 2021 | - | 1.5M | -814K | 6.2M | 2 |
| 2020 | - | -586K | -1.5M | 4.7M | 2 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of December 3, 2024, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Afyx Therapeutics A/S.
As of December 3, 2024, GILFELT REVISION REGISTRERET REVISIONSANPARTSSELSKAB has stepped down as auditor of Afyx Therapeutics A/S.
As of June 18, 2024, Afyx Capital ApS is registered as an owner of Afyx Therapeutics A/S with an ownership share of 66%.
Afyx Therapeutics A/S has published its annual report for 2023. Gross profit came to DKK 6,404,980, and the net result was DKK -2,253,249.
As of April 3, 2024, Søren Mohrsen Kjær has joined the board of directors of Afyx Therapeutics A/S.
On April 3, 2024, the company changed its name from Inphena A/S to Afyx Therapeutics A/S.
About Afyx Therapeutics A/S
Afyx Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2017. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Inphena A/S and Inphena ApS. The management consists of Claus Juan Møller-San Pedro. The board consists of Ole Baadsgaard (chair), Claus Juan Møller-San Pedro, Pia Leah Møller-San Pedro and Søren Mohrsen Kjær. The company is owned by Afyx Capital ApS. The company has 11 employees (2026). In 2025, the company reported a gross profit of DKK 23,138,320 and a net result of DKK 1,518,132 compared with DKK -3,810,585 the year before. Equity in the 2025 report amounted to DKK 36,178,254.
